The Portfolio returned 7.33% gross, significantly outperforming the MSCI World Health Care Index's 3.12% return. Click here ...

For a stock that had been struggling for significance for much of the past year, this dramatic shift was not merely a rally — ...

The average one-year price target for Wave Life Sciences (NasdaqGM:WVE) has been revised to $32.70 / share. This is an increase of 60.82% from the prior estimate of $20.34 dated December 3, 2025. The ...

Discover why Wave Life Sciences Ltd. is a high-risk, high-reward biotech with unique RNA therapies for AATD, obesity, and more. Click for this WVE stock update.

Canaccord analyst Kyle Mikson raised the firm’s price target on Caris Life Sciences (CAI) to $30 from $28 and keeps a Hold rating on the shares.

Through the first three quarters of 2025, M&A activity overtook the entire 2024 total, according to Endpoints News. Editor and founder John Carroll wrote in October this might be the best time in 15 ...

Wave Life Sciences Ltd is a pioneering force in genetic medicine, focusing on creating innovative treatments for serious ...

We have an emerging new entrant in the increasingly crowded weight loss drug space.

Life Sciences ventures face high levels of scientific, clinical and commercial pathway uncertainty, and these uncertainties present many opportunities for entrepreneurial innovation. This course is ...

The developer behind Philadelphia's largest life sciences building says the market needs patience after venture capital ...

Salesforce (NYSE: CRM), the world’s #1 AI CRM, announced today that Novartis (NYSE: NVS), a leading global innovative ...

Scientists have discovered that complex life began evolving much earlier than traditional models suggested. Using an expanded molecular clock approach, the team showed that crucial cellular features ...